Literature DB >> 7944530

Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia?

K P Morris1, J R Skinner, S Hunter, M G Coulthard.   

Abstract

Children with end stage renal failure and anaemia have an increased cardiac index and often gross ventricular hypertrophy. Correction of anaemia with recombinant human erythropoietin (r-HuEpo) for less than six months results in a reduction in the cardiac index without a significant reduction in left ventricular hypertrophy. Seven children receiving dialysis (group 1) were studied to determine whether a reduction in left ventricular hypertrophy would occur after a 12 month period of r-HuEpo. A decrease in the cardiac index was seen by six months, and a significant reduction in left ventricular mass index and cardiothoracic ratio was seen by 12 months. Successful renal transplantation also results in a reduction in the cardiac index and left ventricular hypertrophy, but the relative contributions of correction of anaemia and correction of biochemical disturbance is unknown because they usually improve simultaneously. To investigate this, six children (group 2) who already had a mean haemoglobin concentration of 107 g/l while receiving dialysis were followed up for 12 months after successful transplantation. They showed no significant change in haemoglobin concentration, but a dramatic improvement in biochemistry. There was no significant change in cardiovascular function. Anaemia is the more dominant influence on cardiovascular function in end stage renal failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944530      PMCID: PMC1029940          DOI: 10.1136/adc.71.2.119

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

1.  Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.

Authors:  G Cannella; G La Canna; M Sandrini; M Gaggiotti; G Nordio; E Movilli; R Maiorca
Journal:  Clin Nephrol       Date:  1990-12       Impact factor: 0.975

2.  The clinical course of left ventricular hypertrophy in dialysis patients.

Authors:  P S Parfrey; J D Harnett; S M Griffiths; R Taylor; J Hand; A King; P E Barre
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Regression of left ventricular hypertrophy after renal transplantation. A prospective study.

Authors:  J L Teruel; L Rodriguez Padial; C Quereda; P Yuste; R Marcen; J Ortuño
Journal:  Transplantation       Date:  1987-02       Impact factor: 4.939

4.  Renal transplantation and cardiac function in pediatric patients.

Authors:  S O'Regan; M Y Douste-Blazy; G Ducharme; J C Fouron; A Davignon
Journal:  Clin Nephrol       Date:  1982-05       Impact factor: 0.975

5.  Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.

Authors:  G M London; B Zins; B Pannier; C Naret; J M Berthelot; C Jacquot; M Safar; T B Drueke
Journal:  Kidney Int       Date:  1989-11       Impact factor: 10.612

6.  Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.

Authors:  H Tagawa; M Nagano; H Saito; M Umezu; M Yamakado
Journal:  Clin Nephrol       Date:  1991-01       Impact factor: 0.975

7.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

8.  Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.

Authors:  K P Morris; J R Skinner; S Hunter; M G Coulthard
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin.

Authors:  J L Teruel; J Pascual; M Jiménez; F Liaño; M Rivera; J Martínez; J L Moya; J Ortuño
Journal:  Nephron       Date:  1991       Impact factor: 2.847

10.  Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.

Authors:  J Pascual; J L Teruel; J L Moya; F Liaño; M Jiménez-Mena; J Ortuño
Journal:  Clin Nephrol       Date:  1991-06       Impact factor: 0.975

View more
  5 in total

1.  Homocysteine and left ventricular hypertrophy in children with chronic renal failure.

Authors:  Hakan M Poyrazoğlu; Ruhan Düşünsel; Figen Narin; Zübeyde Gündüz; Nazmi Narin; Musa Karakükçü; Fulya Tahan
Journal:  Pediatr Nephrol       Date:  2003-12-05       Impact factor: 3.714

2.  Hemoglobin target in chronic kidney disease: a pediatric perspective.

Authors:  Sai Ram Keithi-Reddy; Ajay K Singh
Journal:  Pediatr Nephrol       Date:  2008-07-05       Impact factor: 3.714

Review 3.  Anemia in children with chronic kidney disease.

Authors:  Susan M Koshy; Denis F Geary
Journal:  Pediatr Nephrol       Date:  2007-01-24       Impact factor: 3.714

Review 4.  Cardiovascular complications of pediatric chronic kidney disease.

Authors:  Mark M Mitsnefes
Journal:  Pediatr Nephrol       Date:  2006-11-21       Impact factor: 3.714

Review 5.  Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.

Authors:  Gordon Bruce; Peter Schulga; Ben C Reynolds
Journal:  Clin Kidney J       Date:  2022-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.